SCHEMBL13613658

SCHEMBL13613658

COC(=O)c1c(C)cc(F)cc1CBr

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.44
ACHE P22303 1/20 0.44
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.38
SLC6A9 P48067 1/20 0.36
GLO1 Q04760 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
PLA2G2A P14555 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
GCGR P47871 1/20 0.33
CNR2 P34972 1/20 0.33
BDKRB1 P46663 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23089330 0.84 CCR6 (0.37) CYP3A4ACHECA12CA1CA2
SCHEMBL31169205 0.84 KDM4E (0.37) CYP3A4ACHEHPGDPOLBPLA2G2A
SCHEMBL18298430 0.83 MAPT (0.39) HPGDPOLBNPC1RAB9AHSP90AA1
SCHEMBL2025783 0.83 SOS1 (0.35) CYP3A4ACHEHPGDNPC1RAB9A
SCHEMBL10073228 0.82 CYP3A4 (0.55) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL16790432 0.82 CYP3A4 (0.45) CYP3A4ACHEHPGDPOLBCA12
SCHEMBL1104456 0.82 CYP3A4 (0.45) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL29400731 0.82 CYP3A4 (0.45) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL12581658 0.81 CYP3A4 (0.44) CYP3A4ACHEHPGDPOLBGLO1
SCHEMBL2024374 0.80 NOTUM (0.42) BDKRB1HSP90AA1HSP90B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2921480-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-10-11 EP disclosed
US-9777005-B2 Bicyclic heterocyclic compound containing a substituted pyrrole ring TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
US-9732086-B2 2017-08-15 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 CYP3A4 1095/4885ACHE 1263/4885HPGD 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.